The Lesson Of Jevtana: With A Survival Advantage, All Things Are Possible

 
• By Bridget Silverman

The expedited review and approval of Sanofi-Aventis’ oncologic Jevtana (cabazitaxel) shows the power of a clearly demonstrated survival advantage to overcome regulatory hurdles.

More from Archive

More from Pink Sheet